This study is testing a vaccine called VGX-3100 for people with HIV and high-grade anal lesions caused by HPV (a virus that can lead to cancer). The vaccine is made from DNA, which helps the body’s immune system fight tumor cells. Electroporation is a technique that helps cells absorb the vaccine better, boosting the immune response. The main goal is to see if the vaccine helps reduce or eliminate the lesions after 48 weeks.

3 Key Points:

• This study lasts up to 72 weeks with follow-up appointments.
• Participants receive 4 vaccine doses over 24 weeks.
• Researchers will check for any side effects or safety issues.

To join, you need to have a proven diagnosis of anal lesions, be HIV-positive, and meet other health criteria. The study excludes those who have had recent treatments for the lesions, certain medical conditions, or allergies to the vaccine. Participation involves regular visits and tests, and you must agree to use birth control during the study if you could have children. Always consult your doctor to understand the risks and benefits before participating in any clinical study.